Niacin's role in the statin era

Bibliography

• LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999;282:2340-46
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN, Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Arterioscler Thromb Vasc Biol 2004;24:e149-61
   PubMed Web of Science ®Google Scholar
• Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005;45:185-97
   PubMed Web of Science ®Google Scholar
• Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA 2007;298:786-98
   PubMed Web of Science ®Google Scholar
• Canner PL, Berge KG, Wenger NK, Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Olsson AG, Faergeman O, Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian simvastatin survival study (4S). Circulation 1998;97:1453-60
   PubMed Web of Science ®Google Scholar
• Sacks FM, Tonkin AM, Shepherd J, Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the prospective pravastatin pooling project. Circulation 2000;102:1893-900
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH, Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD, ; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Faergeman O, Kastelein JJ, ; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-45
   PubMed Web of Science ®Google Scholar
• Barter P, Gotto AM, LaRosa JC, HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-10
   PubMed Web of Science ®Google Scholar
• Gordon DJ, Probstfield JL, Garrison RJ, High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989;79:8-15
   PubMed Web of Science ®Google Scholar
• Brown BG, Stukovsky KH, Zhao XQ. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. Curr Opin Lipidol 2006;17:631-6
   PubMed Web of Science ®Google Scholar
• Alsheikh-Ali AA, Lin JL, Abourjaily P, Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol. Am J Cardiol 2007;100:1499-1
   PubMed Web of Science ®Google Scholar
• McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med 2004;164:697-705
   PubMed Web of Science ®Google Scholar
• Brown BG, Zhao XQ, Chait A, Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Sullenberger LE, Lee HJ, Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-17
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Villines TC, Stanek EJ, Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009;361:2113-22
   PubMed Web of Science ®Google Scholar
• Karas RH, Kashyap ML, Knopp RH, Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. Am J Cardiovasc Drugs 2008;8:69-81
   PubMed Web of Science ®Google Scholar
• Kashyap ML, McGovern ME, Berra K, Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002;89:672-8
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Davidson MH, McKenney J, Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol 2008;101:1428-36
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Davidson MH, McKenney JM, Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study. J Clin Lipidol 2008;2:79-90
   PubMed Web of Science ®Google Scholar
• McKenney JM, Jones PH, Bays HE, Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis 2007;192:432-7
   PubMed Web of Science ®Google Scholar
• Erqou S, Kaptoge S, Perry PL, Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;302:412-23
   PubMed Web of Science ®Google Scholar
• Scaunu AM, Bamba R. Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations. Am J Cardiol 2008;101(8A):44-7B
   Web of Science ®Google Scholar
• Bays HE, Dujovne CA, McGovern ME, Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the Advicor versus other cholesterol-modulating agents trial evaluation [ADVOCATE]). Am J Cardiol 2003;91:667-72
   PubMed Web of Science ®Google Scholar
• Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering – are they clinically relevant? Eur Heart J 2003;24:225-48
   PubMed Web of Science ®Google Scholar
• Kuvin JT, Dave DM, Sliney KA, Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol 2006;98:743-5
   PubMed Web of Science ®Google Scholar
• Ganji SH, Qin S, Zhang L, Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis 2009;202:68-75
   PubMed Web of Science ®Google Scholar
• Kuvin JT, Ramet ME, Patel AR, A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J 2002;144:165-72
   PubMed Web of Science ®Google Scholar
• Ramet ME, Ramet M, Lu Q, High-density lipoprotein increases the abundance of eNOS protein in human vascular endothelial cells by increasing its half-life. J Am Coll Cardiol 2003;41:2288-97
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 2006;22:2243-50
   PubMed Web of Science ®Google Scholar
• Lee JM, Robson MD, Yu LM, Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 2009;54:1787-94
   PubMed Web of Science ®Google Scholar
• Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899-06
   PubMed Web of Science ®Google Scholar
• Suwaidi JA, Hamasaki S, Higano ST, Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000;101:948-54
   PubMed Web of Science ®Google Scholar
• Warnholtz A, Wild P, Ostad MA, Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study. Atherosclerosis 2009;204:216-21
   PubMed Web of Science ®Google Scholar
• Zhao XQ, Morse JS, Dowdy AA, Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (the HDL atherosclerosis treatment study). Am J Cardiol 2004;93:307-12
   PubMed Web of Science ®Google Scholar
• Alsheikh-Ali AA, Karas RH. Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States food and drug administration adverse event reporting system). Am J Cardiol 2007;99:379-81
   PubMed Web of Science ®Google Scholar
• Grundy SM, Vega GL, McGovern ME, Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002;162:1568-76
   PubMed Web of Science ®Google Scholar
• AIM HIGH: Niacin Plus Statin to Prevent Vascular Events. Available from: http://www.clinicaltrials.gov/ct/show/NCT00120289 [Last accessed 16 May 2010]
   Google Scholar
• HPS2-THRIVE: Heart Protection Study 2: Treatment of HDL to Reduce the Incidence of Vascular Events. Available from: http://www.clinicaltrials.gov/ct/show/NCT00461630 [Last accessed 16 May 2010]
   Google Scholar